KC
IOVA icon

Kepos Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Kepos Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30,800
Closed -$347K – 371
2018
Q3 		$347K Hold
30,800
– – 0.02% 312
2018
Q2 		$394K Buy
+30,800
New +$450K 0.02% 295

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Kepos Capital's IOVA Position: Q4 2018 in Review

Kepos Capital sold out of Iovance Biotherapeutics (IOVA) in Q4 2018, closing a stake of 30,800 shares — an estimated $347K sold.

Kepos Capital first reported a position in IOVA in Q2 2018 and held it in 2 quarters. The position peaked at $394K in Q2 2018. 139 funds tracked by Wall St. Rank hold IOVA as of Q4 2018.

  • Kepos Capital reported no remaining Iovance Biotherapeutics position as of Q4 2018 after selling out during the quarter.
  • Kepos Capital sold 30,800 Iovance Biotherapeutics shares in Q4 2018, an estimated $347K.
  • Kepos Capital first reported a position in Iovance Biotherapeutics in Q2 2018 and held it in 2 quarters.
  • Kepos Capital's Iovance Biotherapeutics position peaked at $394K in Q2 2018.
  • 139 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2018.

Based on Kepos Capital's 13F filing for Q4 2018, filed 13 Feb 2019.